| Literature DB >> 16266204 |
Gayle W Robins1, Lesley J Scott.
Abstract
The angiotensin II receptor antagonist eprosartan is approved for the treatment of essential hypertension and may be administered using a convenient once-daily regimen. The drug is a well tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, independent of blood pressure (BP)-lowering effects. Eprosartan has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies. Unlike ACE inhibitors such as enalapril, eprosartan does not have a tendency to cause persistent nonproductive cough. Accordingly, eprosartan represents a useful therapeutic option in the management of patients with hypertension, including those who have had a stroke and those with co-morbid type 2 diabetes mellitus.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16266204 DOI: 10.2165/00003495-200565160-00012
Source DB: PubMed Journal: Drugs ISSN: 0012-6667 Impact factor: 9.546